More:    MJNA HOME        CANNABIS NEWS        SHOP        CONTACT 

Medical Marijuana, Inc. Major Investment AXIM Biotech Announces First-Ever Successful Achievement of Proprietary cGMP Extraction and Manufacturing Methods for Pure Cannabinoid Molecules

Medical Marijuana, Inc. Major Investment AXIM Biotech Announces First-Ever Successful Achievement of Proprietary cGMP Extraction and Manufacturing Methods for Pure Cannabinoid Molecules

by | Feb 28, 2018 | Axim Biotechnologies, Press Releases

SAN DIEGO, Feb. 28, 2018 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced that its major investment company AXIM® Biotechnologies (OTC:AXIM) (“AXIM”) has successfully executed their...
Medical Marijuana, Inc. Major Investment AXIM Biotech Enters Clinical Study Agreement with University of British Columbia to Begin Clinical Trial On CBD Chewing Gum For Treatment of Drug-Related Psychosis

Medical Marijuana, Inc. Major Investment AXIM Biotech Enters Clinical Study Agreement with University of British Columbia to Begin Clinical Trial On CBD Chewing Gum For Treatment of Drug-Related Psychosis

by | Aug 3, 2017 | Axim Biotechnologies, Press Releases

SAN DIEGO, Aug. 3, 2017 — Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM) has entered into a Clinical...
Medical Marijuana, Inc Major Investment AXIM Biotech Enters Agreement With Israel-Based CRO To Begin Clinical POC Study For Treatment Of Restless Leg Syndrome

Medical Marijuana, Inc Major Investment AXIM Biotech Enters Agreement With Israel-Based CRO To Begin Clinical POC Study For Treatment Of Restless Leg Syndrome

by | Jul 27, 2017 | Axim Biotechnologies, Press Releases

SAN DIEGO, July 27, 2017 — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that its major investment AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM) has entered into a Services...
AXIM Biotech Enters Services Agreement With Israel-Based CRO to Begin Clinical POC Study on CBD and Gabapentin Chewing Gum for Treatment of Restless Leg Syndrome

AXIM Biotech Enters Services Agreement With Israel-Based CRO to Begin Clinical POC Study on CBD and Gabapentin Chewing Gum for Treatment of Restless Leg Syndrome

by | Jul 20, 2017 | Axim Biotechnologies, Press Releases

AXIM Biotechnologies, Inc. (AXIM Biotech) AXIM, +2.42% a world leader in cannabinoid research and development, today announced that it has entered into a Services Agreement with an Israel-based contract research organization (CRO) to begin a clinical proof of concept...

Subscribe for Company Updates

* indicates required

Follow us on

social networks

Home     Company    Education     Careers     Shop

This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

Food and Drug Administration (FDA) Disclosure

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Leaving Our Website Disclaimer: If we have a research link to a website where we sell products or have product information you are now leaving the medicalmarijuanainc.com website. Links to any informational websites are provided solely as a service to our users.

The link provides additional information that may be useful or interesting and has no aliation to the promotion, sale and distribution of Medical Marijuana Inc. products. The link does not constitute an endorsement of these organizations by Medical Marijuana Inc. and none should be inferred. Please view our full Terms Of Use Agreement for more information and the terms and conditions governing your use of this site.

* Cannabidiol (CBD) is a naturally-occurring constituent of the industrial hemp plant.

Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell and distribute hemp based products.

© 2021 Medical Marijuana, Inc. All Rights Reserved.